Intercell's Japanese Encephalitis vaccine safe in Phase III trials
16-Jan-2006
Completion of recruitment for the pivotal safety and the pivotal immunogenicity trial is expected early this year. Results of these Phase III trials are expected in mid 2006. First license applications will be made in the US, EU and Australia.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.